Pyrazoloacridine
- Generic Name
- Pyrazoloacridine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21N5O3
- CAS Number
- 99009-20-8
- Unique Ingredient Identifier
- L24XJN68OW
- Background
Pyrazoloacridine has been used in trials studying the treatment of Lung Cancer, Liver Cancer, Breast Cancer, Melanoma (Skin), and Metastatic Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
Phase 1
Terminated
- Conditions
- Disseminated NeuroblastomaRecurrent Neuroblastoma
- Interventions
- Drug: pyrazoloacridineBiological: filgrastimProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantationOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00053950
- Locations
- 🇺🇸
New Approaches to Neuroblastoma Treatment (NANT), Los Angeles, California, United States
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00005976
- Locations
- 🇺🇸
CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸Medcenter One Health System, Bismarck, North Dakota, United States
🇺🇸Altru Cancer Center, Grand Forks, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath